
“Should You Add Gilead Stock to Your Portfolio? A Closer Look at the 8% Surge After Q4 Earnings”
GILD’s Strong HIV Portfolio: Maintaining Momentum Impressive Guidance for 2025 Gilead Sciences, Inc. (GILD) has long been a leader in the fight against HIV, developing groundbreaking treatments that have revolutionized the way the disease is managed. With a strong portfolio of HIV drugs already on the market, GILD is well positioned to maintain its momentum…